GigaGen
South San Francisco, US · Delaware corporation
Find your way into GigaGen
1,009 people in our graph share verified history with the GigaGen team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows David Johnson · together at Stanford University (overlapped)
.jpeg)
knows the team · via University of California, Berkeley, Haas School of Business
×10knows the team · via Stanford University
GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
Founders & leadership
DJ
David JohnsoninFounder and CEO2010–2021David Johnson is CEO of Waymark Clinical, which operates clinical trials using an AI platform; he previously founded GigaGen, developing recombinant antibody therapies that were sold to Grifols in 2021, and was among Natera's founding members and COO. Johnson holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at UC Berkeley.
CW
Chuck WilsonNamed on SEC filing
CK
Carter KellerNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$36.1M disclosed across 1 round · 2017
▶$36.1MraisedJul 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$36.1MraisedJul 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chuck WilsonDirector
- Carter KellerDirector
- David JohnsonExecutive Officer, Director
- Offering amount
- $36.1M
- Amount sold
- $36.1M
- Proceeds to insiders
- $3M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Amgen Europe22 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
Biogen Idec22 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Exagen20 shared keywordsExagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
Companies competing with GigaGen for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $265K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $912.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $249.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $217.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.1M |
| National Science Foundation | Phase II | 2012 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $205.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $189.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $156.4K |
| Department of Energy | Phase I | 2012 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $201.6K |
| National Science Foundation | Phase I | 2011 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does GigaGen do?
- GigaGen, a subsidiary of Grifols, develops recombinant polyclonal and monoclonal antibody therapies for immunodeficiencies, infectious diseases, transplant rejection, and cancer using single-cell discovery technologies. The company runs a pipeline of drug candidates including a lead CTLA-4 oncology asset and recombinant hyperimmunes for hepatitis B, rabies, and botulinum toxin.
- Who founded GigaGen?
- GigaGen was founded by David Johnson.
- How much funding has GigaGen raised?
- GigaGen has disclosed $36.1M raised across 1 round.
- Where is GigaGen headquartered?
- GigaGen is headquartered in South San Francisco, US.